This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented. At the conclusion of this course, participants will be able to: • Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT • Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice • Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging • Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT Time: 7:30 am - 4:45 pm